Stephanie Parker Palmer

Special Counsel
Full contact info

I can translate any business deal into a written agreement, but I also help clients structure and negotiate transactions to develop and commercialize innovative healthcare products.

Passions

Calligraphy

Baking

Experience

Propella Therapeutics Enters Merger Agreement With Astellas Pharma

November 16, 2023

Cooley advised Propella Therapeutics, a privately held biopharmaceutical company that has leveraged a wholly owned proprietary platform that combines medicinal chemistry with lymphatic targeting to create new oncology drugs, on its merger agreement with Astellas Pharma in which Astellas will acquire Propella through a US subsidiary.

Read more

Related contacts

Aaron Binstock
Partner, Washington, DC
Kenneth Krisko
Partner, Reston
Lindsey O'Crump
Associate, Washington, DC
Danielle Joe
Associate, Washington, DC
David Walsh
Partner, Reston
Xander Lee
Partner, Los Angeles Santa Monica
Megan Browdie
Partner, Washington, DC
Howard Morse
Partner, Washington, DC
Steve Tonsfeldt
Partner, Palo Alto
Christopher Kimball
Partner, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
Mary Maher Lewis
Special Counsel, Reston
Stacey A. Bradford
Special Counsel, Washington, DC
Heather Harrington
Special Counsel, Boston
Stephanie Parker Palmer
Special Counsel, Reston
Stella Sarma
Special Counsel, Brussels
Sharon Connaughton
Special Counsel, Washington, DC
Dov Fiskus
Associate, New York
Richard G.S. Lee
Associate, Washington, DC
Jennifer Don
Associate, Reston
John Forrest
Associate, Boston
Kevin Milgram
Associate, Reston
Carly Mitchell
Partner, Washington, DC
Rick Jantz
Associate, Los Angeles Santa Monica
Virat Gupta
Associate, Washington, DC
Amanda Griggs
Associate, New York
Patricia Myers
Paralegal Specialist, Colorado

Related Practices & Industries

Lexeo Therapeutics Announces $100 Million IPO

November 3, 2023

Cooley advised Lexeo Therapeutics, a clinical-stage gene therapy company advancing gene therapy candidates for genetically defined cardiovascular diseases and a genetically defined subgroup of Alzheimer’s disease, on its approximately $100 million initial public offering.

Read more

Related contacts

Eric Blanchard
Partner, New York
Peter Byrne
Partner, New York
Div Gupta
Partner, New York
Ivor Elrifi
Partner, New York
Matthew Pavao
Partner, Boston
Xander Lee
Partner, Los Angeles Santa Monica
Barbara Mirza
Partner, Los Angeles Santa Monica
Aaron Pomeroy
Partner, Colorado
Phil Mitchell
Partner, New York
Mark Ballantyne
Partner, Reston
Francis Wheeler
Partner, Colorado
Natasha Leskovsek
Of Counsel, Washington, DC
Stephanie Parker Palmer
Special Counsel, Reston
Joseph Lockinger
Special Counsel, Washington, DC
Christophe Beauduin
Special Counsel, New York
Randy Sabett
Special Counsel, Washington, DC
Jennifer Shanley
Special Counsel, New York
Reid Hooper
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC
Dayne Brown
Associate, New York
Ibe Alozie
Associate, Washington, DC
Christopher Nickas
Associate, New York
DeVon Barnett
Associate, Washington, DC
Carly Robinson
Associate, Reston
Calvin Lee
Associate, New York
Jayne M. Munger
Associate, New York
Megan Drill
Associate, San Diego
Erika Freeman
Associate, New York
Mor Agam
Associate, New York
Wyatt Kernell
Associate, New York
Wyatt Kernell
Associate, New York
Alexander Fullman
Associate, New York
Jason Minio
Paralegal Specialist, Boston
Andrew Henderson
Patent Agent, Seattle

Related Practices & Industries

Immatics Announces Collaboration With Moderna

September 11, 2023

Cooley advised Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, on its strategic collaboration with Moderna.

Read more

Related contacts

Kenneth Krisko
Partner, Reston
Stephanie Parker Palmer
Special Counsel, Reston
J. Brian Stalter
Special Counsel, New York
Carly Robinson
Associate, Reston
David D. Suh
Associate, Palo Alto
Freddy Yip
Associate, Hong Kong
Jacqueline Grise
Partner, Washington, DC
Sharon Connaughton
Special Counsel, Washington, DC
Rubin Waranch
Associate, Washington, DC
Alexander Israel
Partner in Charge – Brussels, Brussels
Stella Sarma
Special Counsel, Brussels
Jan Lang
Associate, Brussels
Kimberly Nguyen
Special Counsel, Reston
Liza Hadley
Associate, Boston
Aaron Pomeroy
Partner, Colorado
Amanda Pacheco
Associate, Palo Alto
Rachel Thorn
Partner, New York
Matthew Pavao
Partner, Boston

Related Practices & Industries

Immatics Enters Global Exclusive License Agreement With Bristol Myers Squibb

December 22, 2021

Cooley advised Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, on its license, development and commercialization agreement with Bristol Myers Squibb for its TCR bispecific candidate, IMA401. Lawyers Ken Krisko, Carly Robinson, Brian Stalter and Stephanie Palmer led the Cooley team advising Immatics.

Read more

Related contacts

Kenneth Krisko
Partner, Reston
Carly Robinson
Associate, Reston
J. Brian Stalter
Special Counsel, New York
Stephanie Parker Palmer
Special Counsel, Reston
Nicollette R. Kirby
Associate, Washington, DC
Alexander Israel
Partner in Charge – Brussels, Brussels
Jan Lang
Associate, Brussels
Aaron Pomeroy
Partner, Colorado
Amanda Pacheco
Associate, Palo Alto
Rachel Thorn
Partner, New York
Patrick Van Eecke
Partner, Brussels
Bartholomäus Regenhardt
Associate, Brussels
Stella Sarma
Special Counsel, Brussels
Christine Graham
Special Counsel, London
Douglas Lyles
Senior Research Services & Access Analyst

Related Practices & Industries

Hansa Biopharma Announces Collaboration with Sarepta

October 29, 2020

Hansa biopharma in its license collaboration with Sarepta Therapeutics to develop and promote imlifidase, an antibody-cleaving enzyme, for use as a pre-treatment to enable Sarepta’s AAV gene therapy to be administered for patients with Duchenne muscular dystrophy (DMD) and Limb-girdle muscular dystrophy (LGMD) who may otherwise not be eligible for treatment.

Under the terms of the agreement, Hansa will receive an upfront payment of $10 million and is eligible for additional development, regulatory and sales milestone payments potentially totaling up to $397.5 million. Hansa will book all sales of imlifidase and will earn tiered royalties up to the mid-teens on any incremental gene therapy sales that arise from treating antibody-positive patients enabled through imlifidase pre-treatment.

Related contacts

Kenneth Krisko
Partner, Reston
Stephanie Parker Palmer
Special Counsel, Reston

Related Practices & Industries

View more